Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes

Conclusions:
The combination therapy of ViL and VaL improves both pancreatic beta-cell function and insulin sensitivity, with a reduction of the inflammatory and cell stress milieu in mouse models of T2DM. Our results suggest that this combination therapy exerts additive or even synergistic benefits to treat T2DM.

Source: Cardiovascular Diabetology - November 4, 2013 Category: Cardiology Authors: Katsutoshi MiyagawaTatsuya KondoRieko GotoRina MatsuyamaKaoru OnoSayaka KitanoShuji KawasakiMotoyuki IgataJunji KawashimaTakeshi MatsumuraHiroyuki MotoshimaEiichi Araki Source Type: research